Aw, A Success

A Forbes article entitled, “Genomics: No Longer A Failure,” says that Human Genome Sciences and Vertex Pharmaceuticals are finally living up to the hype promised during Human Genome Project. Human Genome saw positive results in a second study of its lupus drug, Benlysta, and Vertex presented mid-stage results of its hepatitis C drug, telaprevir, that indicated it could work as well if taken twice a day as three times a day, which is how it is currently being tested. Forbes notes that Benlysta would be “one of the first [drugs] to emerge from newfangled efforts to decipher the human genome that started in the early 1990s, amid enormous amounts of hype that it would lead to a huge cornucopia of new drugs.”